ATE192652T1 - Zusammensetzung zur behandlung von preeclampsia und frühgeburt, die ein progestatives mittel und ein stickoxyd-synthäse substrat und/oder donor enthält - Google Patents

Zusammensetzung zur behandlung von preeclampsia und frühgeburt, die ein progestatives mittel und ein stickoxyd-synthäse substrat und/oder donor enthält

Info

Publication number
ATE192652T1
ATE192652T1 AT94924261T AT94924261T ATE192652T1 AT E192652 T1 ATE192652 T1 AT E192652T1 AT 94924261 T AT94924261 T AT 94924261T AT 94924261 T AT94924261 T AT 94924261T AT E192652 T1 ATE192652 T1 AT E192652T1
Authority
AT
Austria
Prior art keywords
preeclampsia
txa2
donor
treatment
composition
Prior art date
Application number
AT94924261T
Other languages
English (en)
Inventor
Robert E Garfield
Chandra Yallampalli
Kristof Dr Chwalisz
Radoslaw Dr Bukowski
Original Assignee
Schering Ag
Garfield Robert
Chandra Yallampalli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag, Garfield Robert, Chandra Yallampalli filed Critical Schering Ag
Application granted granted Critical
Publication of ATE192652T1 publication Critical patent/ATE192652T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT94924261T 1993-07-16 1994-07-18 Zusammensetzung zur behandlung von preeclampsia und frühgeburt, die ein progestatives mittel und ein stickoxyd-synthäse substrat und/oder donor enthält ATE192652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/092,426 US5895783A (en) 1993-07-16 1993-07-16 Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
PCT/EP1994/002368 WO1995002408A1 (en) 1993-07-16 1994-07-18 Combination of a progestational agent and a nitric oxide synthase substrate and/or donor for the treatment of preeclampsia and preterm labor

Publications (1)

Publication Number Publication Date
ATE192652T1 true ATE192652T1 (de) 2000-05-15

Family

ID=22233157

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94924261T ATE192652T1 (de) 1993-07-16 1994-07-18 Zusammensetzung zur behandlung von preeclampsia und frühgeburt, die ein progestatives mittel und ein stickoxyd-synthäse substrat und/oder donor enthält

Country Status (23)

Country Link
US (3) US5895783A (de)
EP (1) EP0708647B1 (de)
JP (1) JP3665068B2 (de)
KR (1) KR100338345B1 (de)
CN (1) CN1095668C (de)
AT (1) ATE192652T1 (de)
AU (2) AU7459194A (de)
BR (1) BR9407069A (de)
CA (1) CA2166873A1 (de)
CZ (1) CZ290938B6 (de)
DE (1) DE69424426T2 (de)
DK (1) DK0708647T3 (de)
ES (1) ES2150497T3 (de)
GR (1) GR3034165T3 (de)
HU (1) HUT73488A (de)
NO (1) NO312335B1 (de)
NZ (1) NZ271077A (de)
PL (1) PL177649B1 (de)
PT (1) PT708647E (de)
RU (1) RU2146143C1 (de)
SK (1) SK282292B6 (de)
UA (1) UA39206C2 (de)
WO (1) WO1995002408A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210918B1 (en) * 1992-10-09 2001-04-03 The Regents Of The University Of California Non-invasive method for detection, diagnosis or prediction of term or pre-term labor
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5811416A (en) * 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US6613757B1 (en) * 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
GB9424694D0 (en) * 1994-12-07 1995-02-01 Wellcome Found Compounds for use in medicine
RU2199346C2 (ru) * 1995-03-14 2003-02-27 Шеринг Аг Применение доноров оксида азота или ингибиторов оксида азота для регулирования раскрытия и растяжения шейки матки
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5898038A (en) * 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6232434B1 (en) 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5906987A (en) * 1997-03-10 1999-05-25 Schering Aktiengesellschaft And Board Of Regents Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors
JPH11217330A (ja) * 1998-01-30 1999-08-10 Sumitomo Pharmaceut Co Ltd 神経栄養因子分泌促進剤
US20040067212A1 (en) * 1998-03-11 2004-04-08 Kabushiki Kaisha Soken Skin conditioner
CA2367002A1 (en) * 1999-03-19 2000-09-28 Michael A. Moskowitz Increasing cerebral bioavailability of drugs
DE60033932T2 (de) * 1999-06-05 2007-12-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford Methode und zusammensetzung zur inhibierung von kardiovaskulärer zellproliferation
US6284790B1 (en) 2000-06-15 2001-09-04 Sachin Gupte Methods of potentiating organic nitrates having vasodilating activity and formulations for the same
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
EP1244152A3 (de) * 2001-01-26 2008-12-03 Toyoda Gosei Co., Ltd. Reflektierende lichtemittierende Diode, reflektierende optische Vorrichtung und Herstellungsverfahren
ATE350041T1 (de) 2001-05-18 2007-01-15 Pantarhei Bioscience Bv Pharmaceutishe zusammensetzung für die hormonersatztherapie
EP1390042B1 (de) 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
WO2002094278A1 (en) 2001-05-23 2002-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
DE60308679T2 (de) 2002-06-11 2007-08-16 Pantarhei Bioscience B.V. Methode zur behandlung oder prävention immunologischer erkrankungen und pharmazeutische zusammensetzung zur solchen anwendung
EP1511498B1 (de) 2002-06-11 2012-11-21 Pantarhei Bioscience B.V. Verfahren zur behandlung der menschlichen haut und hautpflegemittel zur verwendung in diesem verfahren
FR2842108B1 (fr) 2002-07-09 2008-05-02 Effik Composes a base d'hormone et de monoxyde d'azote et leur utilisation en obstetrique et en gynecologie
EP1526856B1 (de) 2002-07-12 2008-01-02 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
UA76641C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
US8987240B2 (en) 2002-10-23 2015-03-24 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
EP1562555A2 (de) * 2002-10-24 2005-08-17 Enos Pharmaceuticals, Inc. L-arginin-formulierungen mit verzögerterfreisetzung und herstellungs- und verwendungsverfahren dafür
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
WO2004071508A1 (en) * 2003-02-14 2004-08-26 Medical Research Council Ip receptor antagonists for the treatment of pathological uterine conditions
US20050113409A1 (en) * 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
JP2007521324A (ja) * 2003-09-29 2007-08-02 エノス ファーマシューティカルズ， インク． 徐放性ｌ−アルギニン調合物並びにその製造法及び使用法
EP1737482A4 (de) * 2004-03-01 2010-09-15 Lumen Therapeutics Llc Zusammensetzungen und verfahren zur behandlung von krankheiten
JP2007536251A (ja) * 2004-05-04 2007-12-13 チルドレンズ メディカル センター コーポレーション 子癇前症の処置のための方法および組成物
WO2006034507A2 (en) 2004-09-24 2006-03-30 Beth Israel - Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
US20070231312A1 (en) * 2006-04-04 2007-10-04 Muench Michael V Nutritional supplement for pregnant females
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
DE602008001783D1 (de) 2007-01-08 2010-08-26 Pantarhei Bioscience Bv Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
CN101778635A (zh) * 2007-07-19 2010-07-14 潘塔希生物科学股份有限公司 妊娠高血压病变或胎儿生长迟缓的治疗或预防
CN102283827A (zh) * 2008-10-16 2011-12-21 四川维信医药科技有限责任公司 单硝酸异山梨酯的新用途
PH12013500107A1 (en) 2010-07-15 2013-03-11 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
UA112755C2 (uk) 2010-07-21 2016-10-25 Олєг Ільіч Епштейн Метод лікування синдрому дефіциту уваги і гіперактивності
MD4183C1 (ro) * 2011-03-30 2013-05-31 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Metodă de tratament al iminenţei de naştere prematură în sarcina multiplă monocorionică
ITMI20122027A1 (it) * 2012-11-28 2014-05-29 Altergon Sa Soluzioni acquose orali di ormoni steroidei e hp¿cd con biodisponibilità ottimizzata
LT3701944T (lt) 2015-06-18 2022-04-11 Estetra Srl Burnoje disperguojamas dozavimo vienetas, kurio sudėtyje yra estetrolio komponentas
ES2671160T3 (es) 2015-06-18 2018-06-05 Mithra Pharmaceuticals S.A. Unidad de dosificación orodispersable que contiene un componente estetrol
SG11202009725XA (en) 2018-04-19 2020-11-27 Estetra Sprl Compounds and their uses for alleviating menopause-associated symptoms
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
RU2724402C1 (ru) * 2020-03-25 2020-06-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции структурных повреждений в плаценте пептидом, имитирующим альфа-спираль B эритропоэтина при ADMA-подобной модели преэклампсии
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1297863A1 (ru) * 1983-06-24 1987-03-23 Горьковский Научно-Исследовательский Педиатрический Институт Способ предупреждени невынашивани беременности
US4855142A (en) * 1987-02-27 1989-08-08 Ciba-Geigy Corporation Pharmaceutical plaster
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5508045A (en) * 1992-10-09 1996-04-16 The Regents Of The University Of California Method and agents for control and management of labor during pregnancy

Also Published As

Publication number Publication date
DK0708647T3 (da) 2000-08-14
CA2166873A1 (en) 1995-01-26
GR3034165T3 (en) 2000-11-30
EP0708647A1 (de) 1996-05-01
AU6981898A (en) 1998-07-16
US5965529A (en) 1999-10-12
US6844320B1 (en) 2005-01-18
SK282292B6 (sk) 2002-01-07
CZ290938B6 (cs) 2002-11-13
KR100338345B1 (ko) 2002-11-23
RU2146143C1 (ru) 2000-03-10
US5895783A (en) 1999-04-20
WO1995002408A1 (en) 1995-01-26
AU7459194A (en) 1995-02-13
BR9407069A (pt) 1996-08-13
DE69424426D1 (de) 2000-06-15
CN1127473A (zh) 1996-07-24
PL177649B1 (pl) 1999-12-31
HUT73488A (en) 1996-08-28
ES2150497T3 (es) 2000-12-01
JP3665068B2 (ja) 2005-06-29
EP0708647B1 (de) 2000-05-10
HU9503854D0 (en) 1996-02-28
CN1095668C (zh) 2002-12-11
KR960703603A (ko) 1996-08-31
DE69424426T2 (de) 2000-10-19
SK6596A3 (en) 1997-06-04
NO312335B1 (no) 2002-04-29
PL312585A1 (en) 1996-04-29
UA39206C2 (uk) 2001-06-15
NO960169D0 (no) 1996-01-15
NZ271077A (en) 1997-11-24
CZ8296A3 (en) 1996-04-17
PT708647E (pt) 2000-08-31
NO960169L (no) 1996-01-15
JPH09500122A (ja) 1997-01-07

Similar Documents

Publication Publication Date Title
ATE192652T1 (de) Zusammensetzung zur behandlung von preeclampsia und frühgeburt, die ein progestatives mittel und ein stickoxyd-synthäse substrat und/oder donor enthält
DK0672041T3 (da) Farmakologisk aktive pyridinderivater og fremgangsmåder til fremstilling deraf
AU548370B2 (en) Surgical fastener
DE69432752D1 (de) Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält
CA2267186A1 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
NO954440D0 (no) 2 pyridylmetylenpolyazamakrocyklo-fosfonsyrer, komplekser og derivater derav, for anvendelse som kontrastmidler
DE3482754D1 (de) Medikament und medikamentoese zusammensetzung zur behandlung und/oder verhinderung von hautkrankheiten, verursacht durch eine entzuendung.
AR004545A1 (es) Derivados de purin-6-ona, procedimientos para su preparacion, el uso de los mismos en la preparacion de medicamentos, medicamentos que los contieneny un procedimiento para preparar dichos medicamentos
DE69423533D1 (de) Zubereitungen zur Behandlung von Impotenz, die ein Alpha-1 inhibitor und ein Alpha-2 inhibitor enthalten
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
EP0274104A3 (de) 13-cis-Retinsäure zur Verwendung in Präparaten gegen alternde Haut
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments
Papadopoulos et al. Hair loss in patients treated with carbimazole
ATE365718T1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
EP0995446A3 (de) Antithrombin III-beta enthaltende Arzneimittelzubereitung
CA819365A (en) Fastener for armlets or bracelets, and for watchbands or straps in particular
CH487612A (de) Gliederarmband, insbesondere für Uhren, und Verfahren zu dessen Herstellung
DE69331193D1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen, die durch endothelzellen und fibrinogen ausgelöst werden
ZA982808B (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
DE59403326D1 (de) Neue bishispidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
UA36475A (uk) Спосіб профілактики коагулопатичних ускладнень у жінок з антенатальною загибеллю плода
UA23901A (uk) Спосіб прогнозування фетоплацентарної недостатності вагітних
ATE227132T1 (de) Zusammensetzung die mindestens einem doppel strangiger rna mit mindestens einem 6- benzyluracile derivat enthält für eine gleichzeitige, getrennte oder zeitausgelegte therapeutische verwendung
RU94020412A (ru) Способ разворота плода
UA30443A (uk) Спосіб прогнозування первинної аменореї у дівчат-підлітків

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee